Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022

Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021

(2022) Mark W. Tenforde et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

(2022) Myron J. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants

(2022) Sara Y Tartof et al.   Lancet Respiratory Medicine

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

(2022) Emi Takashita et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

(2022) Ruth Link-Gelles et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022

(2022) Jason Robert C. Singson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

(2021) Mark G. Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

(2021) Peter J. Embi et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT